Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet

Diabetes Care

Volumn 19, Issue 8, 1996, Pages 843-848

  Gutniak, Mark K ^a,f   Larsson, Hillevi ^b   Heiber, Sonia J ^d   Juneskans, Olof T ^c   Holst, Jens J ^e   Ahrén, Bo ^b  

^a Vällingby Hospital   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d TheraTech Inc   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f Vällingby Medical Center   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHEEK MUCOSA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG HALF LIFE; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOREACTIVITY; INSULIN BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0029840172     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.19.8.843     Document Type: Article

References (37)

1. Lebovitz HE, Feinglos MN: Sulfonylurea drugs: mechanism of antidiabetic action and therapeutic usefulness. Diabetes Care 1:189-198, 1978
2. Scheen AJ, Lefèbvre PJ: Insulin versus insulin plus sulfonylureas in type 2 diabetic patients with secondary failure to sulfonylureas. Diabetes Res Clin Pract 6:S33-S43, 1989
3. Gutniak MK, Karlander SG, Efendic S: Glyburide decreases insulin requirement, increases B-cell response to mixed meal, and does not affect insulin sensitivity: effects of short and long term combined treatment in secondary failure to sulfonylurea. Diabetes Care 10:545-554, 1987
4. Robertson DA, Hale PJ, Nattrass M: Macrovascular disease and hyperinsulinaemia. In Baillère's Clinical Endocrinology and Metabolism. Nattrass M, Hale PJ, Eds. London, Baillire Tindall, 1988, p. 407-424
5. Schmidt WE, Siegel EG, Creutzfeldt W: Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 28:704-707, 1985
6. Holst JJ, Ørskov C, Schwartz TW, Nielsen OV: Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut. FEBS Lett 211:169-174, 1987
7. Mojsov S, Weir GC, Habener JF: Insulinotropin: glucagon-like peptide 1 (7-37) coencoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79:616-619, 1987
8. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF: Preproglucagon gene expression in pancreas and intestine diversifies at the level of posttranslational processing. J Bool Chem 261: 11880-11889, 1986
9. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet ii: 1300-1303, 1987
10. Fehmann HC, Göke R, Göke B: Glucagon-like peptide-1(7-37)/(7-36)amide is a new incretin. Mol Cell Endocrinol 85: C39-C44, 1992
11. Kolligs F, Fehmann H-C, Göke R, Göke B: Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44:16-19, 1995
12. Gutniak MK, Ørskov C, Holst JJ, Ahrén B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322, 1992
13. Nathan DM, Schreiber E, Mojsov S, Habener JF: Insulinotropic action of glucagonlike peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276, 1992
14. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744, 1993
15. Hargrove DM, Nardone NA, Persson LM, Parker JC, Stevenson RW: Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short or long-term administration. Metabolism 44:1231-1237, 1995
16. Gutniak MK, Juntti-Berggren L, Hellström PM, Guenfi A, Holst JJ, Efendic S: GLP-1 (glucagon-like peptide) enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 19:857-863, 1996
17. Gutniak MK, Linde B, Holst JJ, Efendic S: Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 17:1039-1044, 1994
18. Galey WR, Lonsdale HK, Nacht S: The in vitro permeability of skin and buccal mucosa to selected drugs and tritiated water. J Invest Dermatol 67:713-761, 1976
19. Squier CA, Nanny D: Measurement of blood flow in the oral mucosa and skin of the rhesus monkey using radiolabelled microspheres. Arch Oral Biol 30:313-318, 1985
20. Merkle HP, Anders R, Sandow J, Schurr W: Drug delivery of peptides: the buccal route. In Delivery Systems for Peptide Drugs. Davis SS, Tomlinsson E, Eds. New York, Plenum Press, 1986
21. Garran KW, Repta AJ: Buccal drug absorption. I. comparative levels of esterase and peptidase activities in rat and hamster buccal and intestinal homogenates. Int J Pharm 48:189-194, 1988
22. Ørskov C, Rabenhø j L, Wettergren A, Kofod H, Holst JJ: Tissue and plasma concentrations of amidated and glycine extended glucagon-like peptide-1 in humans. Diabetes 43: 535-539, 1994
23. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957, 1995
24. Holst JJ, Bersani M: Assays for the peptide products of somatostatin gene expression. In Methods in Neurosciences, Vol 5: Peptides. Conn PM, Ed. New York, Academic Press, 1991, p. 3-22
25. Ørskov C, Wettergren A, Holst JJ: Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42:658-661, 1993
26. Banga AK, Chien YW: Systemic delivery of therapeutic peptides and proteins. Intern J Pharm 48:15-50, 1988
27. Hermens WAJJ, Merkus FWHM: The influence of drugs on nasal ciliary movement. Pharm Res 4:445-449, 1988
28. Wheatley MM, Dent J, Wheeldon EB, Smith PL: Nasal drug delivery: an in vitro characterization of transepithelial electrical properties and fluxes in the presence and absence of enhancers. J Contr Rel 8:167-177, 1988
29. Brunton RL: The Gaulstonian Lectures Delivered Before the Royal College of Surgeons. London, Macmillan, 1877
30. Lee VHL: Enzymatic barriers to peptide and proteins absorption and use of penetration enhancers to modify absorption. In Delivery Systems for Peptide Drugs. Davis SS, Tomlinsson E, Eds. New York, Plenum Press, 1986
31. Harris D, Robinson JR: Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci 81:1-10, 1992
32. Martin GP, Marriot C, Kellaway IW: Direct effect of bile salts and phospholipids on the physical properties of mucosa. Gut 19:103-108, 1978
33. Hirai S, Yashiki T, Mima H: Mechanisms for the enhancement of the nasal absorption of insulin by surfactants. Intern J Pharm 9:173-177, 1981
34. Fehman HC, Hering BJ, Wolf MJ, Brandhorst H, Brandhorst D, Bretzel RG, Federlin K, Göke B: The effects of glucagon-like peptide-1 (GLP-1) on hormone secretion from isolated human pancreatic islets. Pancreas 11:196-200, 1995
35. Ritzel R, Ørskov C, Holst JJ, Nauck MA: Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 (7-36 amide) after subcutaneous injection in healthy volunteers: dose-response-relationships. Diabetologia 38:720-725, 1995
36. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131, 1995
37. Deacon CF, Pridal L, Holst JJ: Differential organ-specific metabolism of glucagon-like peptide-1 in the anaesthetised pig (Abstract). Diabetologia 38:A167, 1995